Recruiting
Phase 1

hpMRI

Sponsor:

M.D. Anderson Cancer Center

Code:

NCT04589624

Conditions

Thyroid Gland Carcinoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Accepted

Interventions

Hyperpolarized Carbon C 13 Pyruvate

Magnetic Resonance Imaging

Magnetic Resonance Imaging

Study Details

Brief summary:

This trial investigates whether hyperpolarized magnetic resonance imaging (hpMRI) can predict treatment response in patients with thyroid cancer and other malignancies of the head and neck undergoing radiation therapy and/or receiving systemic therapy before surgery. An hpMRI is like a standard MRI but involves the use of an imaging contrast agent called hyperpolarized 13-C-pyruvate. Diagnostic procedures, such as hpMRI, may predict a patient's response to treatment and may help plan the best treatment.

Conditions

Thyroid Gland Carcinoma

Study ID

NCT04589624

Start date

Aug 12, 2020

Status verified date

May, 2026

Completion date

May 31, 2027

Anticipated

Primary completion date

May 31, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Accepted

Inclusion Criteria:

  • Be willing and able to provide informed consent
  • Be informed of the investigational nature of this study
  • Be diagnosed with thyroid cancer and other malignancies of the head and neck with intent for treatment

Exclusion Criteria:

  • Have a history of severe claustrophobia
  • Have electrically, magnetically or mechanically activated implants that would preclude magnetic resonance imaging (MRI)
  • Have a history of cardiac arrhythmia
  • Have an allergy to Gadavist intravenous contrast
  • Estimated glomerular filtration rate (eGFR) < 30
  • If female, be pregnant or breast feeding at time of consent

Study Design

Enrollment

42 participants

Anticipated

Allocation

Non randomized

Intervention Model

Parallel Assignment

Primary purpose

Diagnostic

Interventions and Outcome Measures

Arms

active comparator: Arm I ( Health Volunteer MRI)

Healthy volunteers undergo MRI over 30 minutes.

experimental: Arm II (Thyroid Cancer Patient and other malignancies of the head and neck hpMRI)

Patients with thyroid cancer and other malignancies of the head and neck undergo hpMRI over 30 minutes at baseline, and at 1 week after the initiation of treatment. During the scan, patients also receive hyperpolarized 13-C-pyruvate IV over 30 seconds and may receive a standard MRI contrast agent at the discretion of the treating physician.

Interventions

Hyperpolarized Carbon C 13 Pyruvate

Given IV

Magnetic Resonance Imaging

Undergo MRI

Magnetic Resonance Imaging

Undergo hpMRI

Primary outcome measure

  • Metabolic imaging data from hyperpolarized magnetic resonance imaging (hpMRI) methods [ Time Frame: 1 year ]

Central Contacts and Locations

Central contacts

Stephen Y Lai

713-792-6528sylai@mdanderson.org

Locations

M D Anderson Cancer Center

Recruiting

Houston, Texas, United States, 77030

Contacts

Stephen Y. Lai

713-792-6528

Principal Investigator:

Stephen Y. Lai

More Information

Sponsor

M.D. Anderson Cancer Center

Last update posted

May 22, 2026

Last verified

May, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by M.D. Anderson Cancer Center on 2026-05-22.